Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country…

Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country…

Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country…

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and blindness, especially with the development of diabetic…

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal (IVT) pharmacotherapy approvals across different drug…

Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-…

The DR / DME therapy market will grow moderately over the forecast period (6.6% annual growth through 2029); this growth will be due largely to: The launch of five new therapeutic options…

Patients with diabetic retinopathy (DR) experience retinal damage that can lead to vision impairment and eventual blindness, especially with the development of diabetic macular edema (DME). DME…

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…

Diabetic macular edema (DME) is the accumulation of fluid in the macula due to leaking blood vessels resulting from diabetic retinopathy. Therapies targeting vascular endothelial growth factor (…

With the availability of multiple approved products for the treatment of diabetic macular edema (DME) in the EU5, including Bayer HealthCare’s Eylea, Novartis’s Lucentis, Allergan’s Ozurdex,…

Vascular endothelial growth factor (VEGF) inhibitors—approved agents Eylea (Regeneron) and Lucentis (Roche/Genentech), and off-label Avastin (Roche/Genentech)—are the treatment mainstays for…